

1 COVID-19 symptoms at hospital admission vary with age  
2 and sex: ISARIC multinational study

3

4 **Authors**

5 ISARIC Clinical Characterisation Group \*

6

7 \* Members listed at end of manuscript

8

9

10 **Correspondence to**

11 Dr Mark G Pritchard

12 Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of

13 Oxford, Oxford, UK

14 Tel: 07973163696

15 [mark.pritchard@ndm.ox.ac.uk](mailto:mark.pritchard@ndm.ox.ac.uk)

16 ORCID 0000-0003-1726-8989

17

18 **Summary**

19 Adults over 60 and children admitted to hospital with COVID-19 are less likely to have typical

20 symptoms. Nausea and vomiting are common atypical presentations under 30 and confusion over

21 60. Women are less likely to experience typical symptoms than men.

22

23

## 24 Abstract

## 25 Background

26 The ISARIC prospective multinational observational study is the largest cohort of hospitalized  
27 patients with COVID-19. We present relationships of age, sex, and nationality to presenting  
28 symptoms.

## 29 Methods

30 International, prospective observational study of 60 7109 hospitalized symptomatic patients with  
31 laboratory-confirmed COVID-19 recruited from 43 countries between 30 January and 3 August 2020.  
32 Logistic regression was performed to evaluate relationships of age and sex to published COVID-19  
33 case definitions and the most commonly reported symptoms.

## 34 Results

35 'Typical' symptoms of fever (69%), cough (68%) and shortness of breath (66%) were the most  
36 commonly reported. 92% of patients experienced at least one of these. Prevalence of typical  
37 symptoms was greatest in 30- to 60-year-olds (respectively 80%, 79%, 69%; at least one 95%). They  
38 were reported less frequently in children ( $\leq 18$  years: 69%, 48%, 23%; 85%), older adults ( $\geq 70$  years:  
39 61%, 62%, 65%; 90%), and women (66%, 66%, 64%; 90%; vs men 71%, 70%, 67%; 93%). The most  
40 common atypical presentation under 60 years of age was nausea and vomiting, and over 60 years  
41 was confusion. Regression models showed significant differences in symptoms with sex, age and  
42 country.

## 43 Interpretation

44 Adults over 60 and children admitted to hospital with COVID-19 are less likely to present with typical  
45 symptoms. Nausea and vomiting are common atypical presentations under 30 years. Confusion is a  
46 frequent atypical presentation of COVID-19 in adults over 60 years. Women are less likely to  
47 experience typical symptoms than men.

48 **Keywords**

49 age group, COVID-19, SARS-CoV-2, sex, symptoms, diagnosis, case definition

50

## 51 Background

52 Despite the pandemic's immense human cost, enormous economic toll, and extensive research  
53 response, the precise clinical characteristics of COVID-19 remain unclear [1]. At the start of the  
54 outbreak, COVID-19 was broadly characterised as a severe respiratory illness presenting with fever,  
55 cough and an atypical pneumonia [2-5]. Altered sense of taste and smell have since been found to  
56 be strongly associated with the disease [6, 7]. However, a review of 77 observational studies found  
57 substantial proportions of patients presenting with less typical symptoms [8].

58 The World Health Organization's (WHO) clinical criteria for suspected COVID-19 is either a  
59 combination of acute fever and cough, or a combination of three or more of fever, cough, general  
60 weakness and fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anorexia, nausea and  
61 vomiting, diarrhoea, and altered mental status [9]. Clinical criteria from the Centers for Disease  
62 Control and Prevention in the United States are at least two of fever, chills, rigors, myalgia,  
63 headache, sore throat, and new olfactory and taste disorder, or at least one of cough, shortness of  
64 breath or difficulty breathing [10]. Public Health England's definition of possible COVID-19 is  
65 individuals with a new cough or temperature  $\geq 37.8$  °C, or a loss or change in sense of smell or taste  
66 [11]. The European Centre for Disease Prevention and Control clinical criteria are at least one of  
67 cough, fever, shortness of breath, or sudden onset anosmia, ageusia or dysgeusia [12].

68 Defining presenting symptoms of COVID-19 is further complicated by clinical experience  
69 suggesting that patients frequently present with atypical symptoms other than cough, fever and  
70 shortness of breath. This variation in the clinical characterisation of COVID-19 is problematic, as case  
71 definitions are used to guide clinical diagnosis, disease surveillance, and public health interventions.

72 The International Severe Acute Respiratory and Emerging Infection Consortium  
73 (ISARIC)/WHO Clinical Characterisation Protocol for Severe Emerging Infections is a standardized  
74 protocol for investigation of severe acute infections by pathogens of public health interest [13, 14].  
75 Here we present an analysis of how symptoms of patients admitted to hospital with confirmed  
76 COVID-19 vary by age and sex.

## 77 Materials and methods

### 78 Study population, variables and measurement

79 Patients of any age admitted to hospital with suspected or confirmed COVID-19 were eligible for  
80 recruitment. This analysis was limited to patients admitted to hospital between 30 January and 3  
81 August 2020 with symptomatic COVID-19, confirmed according to sites' local laboratory methods.  
82 We excluded asymptomatic patients admitted to hospital solely for isolation, and patients admitted  
83 for other conditions who subsequently developed COVID-19 symptoms. Variables used in this  
84 analysis were age, sex at birth, symptoms, date of symptoms onset, SARS-CoV-2 confirmation, and  
85 country of recruitment. To allow proportions to be calculated with a reliable denominator, only  
86 symptoms specified on the case report forms were included in this analysis.

87 This observational study required no change to clinical management and permitted  
88 enrolment in other research. The study was approved by the World Health Organization Ethics  
89 Review Committee (RPC571 and RPC572). Local ethics approval was obtained for each participating  
90 country and site according to local requirements. Informed consent was obtained where required by  
91 local ethics committees. In many jurisdictions, ethics committees and public health authorities  
92 approved a waiver of consent.

### 93 Study design and setting

94 The ISARIC cohort is an international prospective observational study of patients admitted to  
95 hospital with COVID-19. Data were collected via electronic 'Core' and 'Rapid' ISARIC case report  
96 forms [15], and through aligned forms by ISARIC-4C Coronavirus Clinical Characterisation Consortium  
97 in the United Kingdom [16] and the COVID-19 Critical Care Consortium [17]. Investigators from 41  
98 countries used Research Electronic Data Capture (REDCap, version 8.11.11, Vanderbilt University,  
99 Nashville, Tenn.) to contribute their data to a central database hosted by the University of Oxford.  
100 Additional data were submitted by investigators not using the University of Oxford REDCap database  
101 from Malaysia, Russia [18], and Spain. The primary objective of this analysis was to investigate how

102 symptoms of patients admitted to hospital with confirmed COVID-19 vary by age and sex.

103 Secondly we investigated how sensitivity of clinical case definitions varied among these

104 populations, and explored heterogeneity among countries.

## 105 Analysis

106 Data were converted to Study Data Tabulation Model (version 1.7, Clinical Data Interchange

107 Standards Consortium, Austin, Tex.). We excluded patients who had all symptoms recorded as

108 missing or unknown, and those with missing age, sex, country or onset date. Continuous variables

109 were expressed as median with interquartile range (IQR), and categorical variables as counts with

110 percentages. We tested for differences between female and male patients using Wilcoxon rank-sum

111 tests for continuous variables and chi-square tests for categorical variables. We grouped patients

112 into ten-year age bands (with a single group  $\geq 90$  years). We plotted most frequently reported

113 symptoms by age group, presenting missing data as a third category. We collated symptoms

114 according to four sets of clinical criteria, based on published criteria [9-12] modified to omit

115 symptoms with large numbers of missing data:

- 116 1. Fever plus cough; or any three of fever, cough, fatigue, headache, myalgia, sore throat,  
117 rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion;
- 118 2. Cough or shortness of breath; or any two of fever, myalgia, headache, and sore throat;
- 119 3. Cough or fever;
- 120 4. At least one of cough, fever, and shortness of breath.

121 Patients with missing details of cough, fever or shortness of breath were omitted from the

122 composite groups; patients missing details of symptoms included in the lists of criteria 1 and 2 were

123 classified according to their non-missing symptoms. We plotted proportions of patients meeting

124 each set of criteria by ten-year age group with 95% confidence intervals (CI) calculated using the

125 Clopper–Pearson method.

126 We used logistic regression to identify associations of age and sex with the twelve most

127 prevalent symptoms. Age group and sex were included as fixed effects, with country as a random

128 intercept. To display heterogeneity between countries on the same scale as the fixed effects, we  
129 plotted median odds ratios (MOR), which quantify variation between countries by comparing odds  
130 of an outcome between randomly chosen persons in different clusters who share covariates [19].  
131 MORs are defined as a comparison of the greater propensity group to the lower propensity group, so  
132 lie in the range one to infinity [19].

133 79% of patients were recruited in a single country. As a sensitivity analysis, we repeated the  
134 analysis excluding patients from this country. Finally, we plotted age-stratified symptom frequencies  
135 for each country with at least 250 patients.

136 No minimum sample size was calculated. All significance tests were two-tailed. Analyses  
137 were performed using R (version 4.0.3, R Foundation for Statistical Computing, Vienna, Austria) with  
138 packages including *binom*, *Epi*, *ggplot2*, *lme4*, *sjstats*, *tableone*, and *tidyverse*.

## 139 Results

140 Data were available for 997623 patients. We excluded 247336 who did not have documented SARS-  
141 CoV-2 confirmation, 3290 with missing data, and 5794 who developed COVID-19 after admission to  
142 hospital. 6094 patients were admitted to hospital with asymptomatic COVID-19, with the greatest  
143 proportion in the age-band 10 to 20 years (46%). We included 607109 patients (Figure 1), recruited  
144 from 394 sites in 43 countries (Supplementary Table 1), in this analysis. The median age of included  
145 patients was 70 years (IQR 54–82; Table 1). 929 (1.5%) were 18 years old or younger. Age  
146 distribution of patients varied among countries, between a median of 10 years in Poland, and 73  
147 years in the United Kingdom (Supplementary Figure 1). 347641 (58%) patients were male.

148 The most frequently reported symptoms were fever, cough and shortness of breath (Table  
149 2). These symptoms were each more prevalent in male patients, whereas less typical symptoms such  
150 as confusion, nausea and vomiting, diarrhoea, chest pain, headache and abdominal pain were more  
151 prevalent in female patients. The greatest sex-related difference was for nausea and vomiting,  
152 reported by 23% of female patients but only 16% of male patients. For most symptoms, the greatest

153 prevalence was reported in adults aged between 30 and 60 years, decreasing toward extremities of  
154 age (Figure 2). Frequency of confusion increased with age. Large numbers of patients had missing  
155 data for anorexia, severe dehydration, altered sense of taste and smell, and inability to walk as these  
156 were not included on all case report forms. Altered sense of taste and smell, which we had excluded  
157 from the composite criteria, were experienced by only 7.4% and 6.2% respectively of patients with  
158 non-missing data.

159 Data on cough, fever or shortness of breath were missing for 3446 patients. The composite  
160 clinical criteria were calculated for the remaining 567663 patients. Each set of criteria was met by a  
161 greater proportion of patients aged 30 to 60 years than those toward either extreme of age (Figure  
162 3). The criteria based on WHO's clinical criteria [9] (fever plus cough; or any three of fever, cough,  
163 fatigue, headache, myalgia, sore throat, rhinorrhoea, shortness of breath, nausea and vomiting,  
164 diarrhoea, and confusion) were met by 407911 (72%) patients, but only 51% of those aged 18 years  
165 and under, and 67% of those aged 70 years or over. The most sensitive criteria were at least one of  
166 cough, fever and shortness of breath, met by 527041 (92%) participants. These criteria were met by  
167 85% aged 18 years and under, and 90% of those aged 70 years or over. Each set of criteria were met  
168 by a greater proportion of male than female patients (Table 2).

169 For the 4622 patients whose symptoms did not meet any assessed case definitions, the most  
170 frequent symptom was confusion (47%; Table 3). This increased with age to 66% of those aged 90  
171 years or older. Nausea and vomiting, and abdominal pain were the most common symptoms for  
172 people less than 60 years old who had not met any of the case definitions.

173 In the logistic regression models (Figure 4), similar associations between age and symptoms  
174 were seen after adjustment for sex and relationship of onset to admission date as in the unadjusted  
175 bar charts. Confusion increased with age. Nausea and vomiting, headache, abdominal pain, and sore  
176 throat were each more frequent in younger age groups, decreasing with age. The 95% CI for sex  
177 excluded one for most symptoms, but for most the point estimate was close to one. Male patients  
178 had greater odds of fever, cough and shortness of breath, and lower odds of gastrointestinal



179 symptoms of nausea and vomiting, diarrhoea, abdominal pain, chest pain, headache and sore throat.  
180 The median odds ratio for heterogeneity between countries was greater than the relationship with  
181 sex in all symptoms. It was of similar magnitude to the relationship with age for most symptoms. For  
182 each symptom, heterogeneity between countries was of a similar magnitude to the effect of age,  
183 and a greater magnitude than sex.

184 47 280 (79%) patients were included from the United Kingdom. Excluding these patients,  
185 the patterns of symptoms were similar to the main analysis (Supplementary Figure 2). The peak  
186 prevalence of fever, cough and shortness of breath was in 70- to 80-year-olds, and fatigue increased  
187 with age. Below the age of 50 years, the clinical case definitions tended to be less sensitive in the  
188 analysis excluding the United Kingdom than in the analysis including it; above the age of 70 years  
189 each tended to be more sensitive (grey lines in Figure 3). Within countries, the baseline prevalence  
190 of each symptom varied but patterns within countries were broadly similar to the overall results  
191 (Supplementary figures 3–14).

## 192 Discussion

193 The ISARIC prospective multinational cohort study is the largest cohort of patients admitted to  
194 hospital with COVID-19. In this report, we confirmed a relationship between patients' symptoms and  
195 their age and sex. The 'typical' COVID-19 symptoms occur most frequently in adults aged 30 to 60  
196 years. Commonly used case definitions in use can miss up to half of children and a third of adults  
197 over 70 years who are admitted to hospital with COVID-19.

198 Our results support the findings of smaller cohort studies that atypical symptoms are more  
199 common in older adults [21], and correlate with similar findings of atypical presentations for  
200 pneumonia, bacteraemia and coronary artery disease [22, 23]. A lower prevalence of symptoms in  
201 children and young people has previously been suggested [24, 25], but this is the first large  
202 international cohort to collect data prospectively from both adults and children.

203 Separate analyses of the ISARIC-4C data have identified fever, cough and shortness of breath

204 as frequently co-occurring clusters of symptoms [26, 27]. In children, the next most frequent cluster  
205 consisted of systemic, enteric and mucocutaneous symptoms [26]. For adults, other clusters  
206 consisted of non-specific viral symptoms, gastrointestinal symptoms, upper respiratory symptoms,  
207 neurological symptoms, and symptoms of bronchospasm [27]. Those data were included in this  
208 global dataset so the results of these analyses are not independent of our results.

209 We found that differences in symptoms by sex were statistically significant but generally of  
210 smaller magnitude. Typical symptoms of fever, cough and shortness of breath were more common  
211 in men than in women; all other symptoms were equal or more common in female patients. A  
212 cohort of non-hospitalized patients with COVID-19 in Poland found greater differences in symptoms  
213 of lack of appetite (55% of women, 36% of men) and taste disorder (53% women, 40% men) [28].  
214 We are unable to determine from our data whether these differences reflect differences in health-  
215 seeking behaviour between men and women, or a biological difference in their response to the  
216 infection. Elaboration of this difference should be a goal of future research.

217 Our results suggest considerable heterogeneity among countries. We have not attempted to  
218 elicit reasons for heterogeneity. Potential reasons include cultural idiosyncrasies in reporting  
219 symptoms, and hospitals' criteria for admission and testing. It might also reflect differences in local  
220 patient recruitment. Researchers in some countries may be unwilling to recruit confused patients  
221 due to requirements for consent, whereas in others the requirement for consent has been waived or  
222 could be obtained from a proxy.

223 We explored the effect of using the country of recruitment as a random effect in regression  
224 models and by repeating the analysis excluding the largest country. Each analysis suggested an  
225 underlying pattern of lower frequencies of typical symptoms in children and older adults. Therefore,  
226 although the prevalence of each symptom reported in this study may not apply to all settings, we  
227 have evidence to support the possibility of age-dependent differences internationally.

228 The size of this cohort is a strength. To our knowledge, it is the largest cohort of hospitalized  
229 COVID-19 patients in the world. However, the study has several limitations. Firstly, almost 80% of

230 patients were recruited in a single country. Moreover, less than 1% of patients were recruited from  
231 low- or lower-middle-income countries. Secondly, the cohort overwhelmingly includes older adults,  
232 with only 1.8% of the cohort aged 18 years or younger. Thirdly, our analysis includes only patients  
233 who were hospitalized with COVID-19 and who had a laboratory-confirmed diagnosis. This patient  
234 population is more likely to be severely unwell and more likely to exhibit symptoms typically  
235 associated with COVID-19 than people who were managed in the community or whose disease has  
236 not been recognized. Accordingly, the reporting of ‘typical’ COVID-19 symptoms in this cohort is  
237 likely to be an overestimate of the population prevalence. Symptoms are subjective and cannot be  
238 externally verified. Some differences for children may reflect that symptoms could only be recorded  
239 if a caregiver recognised the symptom or the child had the appropriate vocabulary to describe it.  
240 Similarly, some symptoms may be under-reported in elderly patients if there are difficulties in  
241 communication, for example due to delirium. As such, the generalizability of estimates of our  
242 symptom prevalence is limited. Similarly, there is a shortage of studies conducted outside of high-  
243 income countries: a recent scoping review of clinical characteristics of COVID-19 identified no large  
244 cohorts in non-high-income countries except China [8].

245         The absence of a control group of patients without COVID-19 in this dataset prevented  
246 estimation of specificity or positive and negative predictive values. We are therefore prevented from  
247 advocating changes to clinical case definitions, as such decisions inevitably require a balance of false-  
248 positive and false-negative rates. However, given the prevalence of atypical symptoms in our cohort,  
249 we can confidently suggest that reliance on clinical case definitions may result in missing cases of  
250 COVID-19, especially among children and older adults. Non-healthcare professionals making  
251 decisions regarding isolation may be especially vulnerable to missing cases of COVID-19 by adhering  
252 to a clinical case definition too strictly.

253         The reported prevalence of COVID-19 may also rely on a strict interpretation of case  
254 definitions. In settings where comprehensive contact tracing is planned, or there is easy access to  
255 microbiological testing, a highly sensitive case definition is desirable. However, where decisions are

256 based on clinical diagnoses, it is important to recognize other pathogens that can cause similar  
257 constellations of symptoms. The addition of symptoms such as confusion or gastrointestinal  
258 symptoms to the COVID-19 case definition could increase sensitivity, but at the cost of reduced  
259 specificity. Changes in the senses of taste and smell have recently been added to case definitions.  
260 Our data suggest that these criteria would detect only a small proportion of patients admitted to  
261 hospital with COVID-19 who were omitted by other definitions.

262         These results highlight the need to consider COVID-19 even if individuals do not display  
263 typical symptoms of the disease. This is especially the case in children and older adults. Given that  
264 our results are likely to overestimate the sensitivity of the clinical criteria currently used to identify  
265 patients for testing, our results suggest a lower limit to the proportion of people in the community  
266 with COVID-19 who would not be identified. Addition of confusion as a symptom would increase the  
267 sensitivity of case definitions for older adults; and inclusion of nausea and vomiting or abdominal  
268 pain would increase sensitivity for children and young adults. The high proportion of asymptomatic  
269 patients identified in patients aged 10 to 20 years suggests that universal screening in these ages  
270 could be beneficial when there is widespread community circulation of COVID-19. Ongoing data  
271 collection outside high-income countries is needed to establish whether alternative case definitions  
272 are needed in different settings. Work is also ongoing to determine whether some constellations of  
273 symptoms are associated with better or poorer outcomes than others.

## 274 **Declarations**

## 275 **Funding**

276 This work was supported by the Department for International Development and Wellcome Trust  
277 [215091/Z/18/Z]; the Bill and Melinda Gates Foundation [OPP1209135]. Country-specific support  
278 was provided by the Canadian Institutes of Health Research Coronavirus Rapid Research Funding  
279 Opportunity [OV2170359]; the Health Research Board Ireland [CTN Award 2014-012]; National  
280 Institute for Health Research (NIHR) [award CO-CIN-01]; the Medical Research Council (MRC) [grant

281 MC\_PC\_19059]; the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic  
282 Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration  
283 with Liverpool School of Tropical Medicine and the University of Oxford [award 200907]; NIHR HPRU  
284 in Respiratory Infections at Imperial College London with PHE [award 200927]; Liverpool  
285 Experimental Cancer Medicine Centre [grant reference C18616/A25153]; NIHR Biomedical Research  
286 Centre at Imperial College London [IS-BRC-1215-20013]; EU Platform for European Preparedness  
287 Against (Re-)emerging Epidemics (PREPARE) [FP7 project 602525]; National Institutes of Health (NIH)  
288 [UL1TR002240]; and NIHR Clinical Research Network infrastructure support. We acknowledge the  
289 generous support of all ISARIC Partners who have contributed data and expertise to this analysis,  
290 with or without dedicated funding. The views expressed are those of the authors and not necessarily  
291 those of the funders or institutions listed above.

## 292 [Competing interests](#)

293 M. Cheng declares grants from McGill Interdisciplinary Initiative in Infection and Immunity, and  
294 Canadian Institutes of Health Research; and personal fees from GEn1E Lifesciences (as a member of  
295 the scientific advisory board) and nplex biosciences (as a member of the scientific advisory board);  
296 M. Cummings and M. O'Donnell participated as investigators for completed and ongoing clinical  
297 trials evaluating the efficacy and safety of remdesivir (sponsored by Gilead Sciences) and  
298 convalescent plasma (sponsored by Amazon), in hospitalized patients with COVID-19 – support for  
299 this work is paid to Columbia University; J. C. Holter declared grants from Research Council of  
300 Norway [grant 312780], and Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner, during the  
301 conduct of the study; A.Kimmoun declared personal fees (payment for lectures) from Baxter,  
302 Aguetant, Aspen; D. Kumar declared grants and personal fees from Roche, GSK and Merck, and  
303 personal fees from Pfizer and Sanofi; F.X. Lescure declared personal fees (payment for lectures) from  
304 Gilead, MSD; and travel/accommodation/meeting expenses from Astellas, Eumedica, MSD; A.  
305 Pesenti declared personal fees from Maquet, Novalung/Xenios, Baxter, and Boehringer Ingelheim; S.  
306 Shrapnel reported grants from Prince Charles Hospital Foundation during the conduct of the study,

307 and concurrently performed data analytics for the COVID-19 Critical Care Consortium; R. Tedder  
308 reports grants from MRC/UKRI during the conduct of the study, and has a patent United Kingdom  
309 Patent Application No. 2014047.1 “SARS-CoV-2 antibody detection assay” issued; J. Troost declared  
310 personal fees from General Electric and Procter and Gamble.

### 311 **Ethics approval**

312 This observational study required no change to clinical management and permitted enrolment in  
313 other research. The study was approved by the World Health Organization Ethics Review Committee  
314 (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site  
315 according to local requirements.

### 316 **Consent to participate**

317 Informed consent was sought where required by local ethics committees. In many jurisdictions,  
318 ethics committees and public health authorities approved a waiver of consent to collect anonymised  
319 clinical data in the context of this public health emergency.

### 320 **Availability of data and materials**

321 We welcome applications for UK data through the ISARIC 4C Independent Data and Material Access  
322 Committee (<https://isaric4c.net>). Requests for access to non-UK data can be sent to  
323 [covid19@iddo.org](mailto:covid19@iddo.org).

### 324 **Authors' contributions**

325 Author contributions are listed in the supplementary material.

### 326 **Acknowledgements**

327 We are extremely grateful to the frontline clinical and research staff and volunteers, who collected  
328 this data in challenging circumstances, and the generosity of the patients and their families for their  
329 individual contributions in these difficult times. This work uses data provided by patients and  
330 collected by the health institutions and authorities in each country. In the UK, this study involves the  
331 National Health Service as part of their care and support #DataSavesLives. We also acknowledge the

332 support of Jeremy J Farrar, Nahoko Shindo, Devika Dixit, Nipunie Rajapakse, Andrew Davison, David  
333 Barr, Lyndsey Castle, Martha Buckley, Debbie Malden, Katherine Newell, Kwame O’Neill,  
334 Emmanuelle Denis, Claire Petersen, Scott Mullaney, Sue MacFarlane, Nicole Maziere, Julien  
335 Martinez, Oslem Dincarslan, Annette Lake and the Irish Critical Care Trials Group. We appreciate the  
336 strong collaboration of the WHO Clinical Data Platform Team, including Silvia Bertagnolio, Soe Soe  
337 Thwin, and Janet Diaz.

### 338 **ISARIC Clinical Characterisation Group**

339 Sheryl Ann Abdukahil, Ryuzo Abe, Laurent Abel, Lara Absil, Andrew Acker, Shingo Adachi, Elisabeth  
340 Adam, Diana Adrião, Kate Ainscough, Ali Ait Hssain, Younes Ait Tamlihat, Takako Akimoto, Tala Al-  
341 Dabbous, Abdulrahman Al-Fares, Eman Al Qasim, Razi Alalqam, Beatrice Alex, Kévin Alexandre, Huda  
342 Alfoudri, Kazali Enagnon Alidjnou, Jeffrey Aliudin, Clotilde Allavena, Nathalie Allou, João Alves, Rita  
343 Alves, Maria Amaral, Heidi Ammerlaan, Phoebe Ampaw, Roberto Andini, Claire Andrejak, Andrea  
344 Angheben, François Angoulvant, Séverine Ansart, Massimo Antonelli, Carlos Alexandre Antunes De  
345 Brito, Yaseen Arabi, Irene Aragao, Antonio Arcadipane, Lukas Arenz, Jean-Benoît Arlet, Christel  
346 Arnold-Day, Lovkesh Arora, Elise Artaud-Macari, Angel Asensio, Jean Baptiste Assie, Anika Atique,  
347 Johann Auchabie, Hugues Aumaitre, Laurène Azemar, Cécile Azoulay, Benjamin Bach, Delphine  
348 Bachelet, J. Kenneth Baillie, Erica Bak, Agamemnon Bakakos, Firouzé Banisadr, Renata Barbalho,  
349 Wendy S. Barclay, Michaela Barnikel, Audrey Barrelet, Cleide Barrigoto, Romain Basmaci, Diego  
350 Fernando Bautista Rincon, Alexandra Bedossa, Sylvie Behilill, Aleksandr Beljantsev, David Bellemare,  
351 Anna Beltrame, Marine Beluze, Nicolas Benech, Dehbia Benkerrou, Suzanne Bennett, Luís Bento,  
352 Jan-Erik Berdal, Delphine Bergeaud, Lorenzo Bertolino, Simon Bessis, Sybille Bevilacqua, Krishna  
353 Bhavsar, Felwa Bin Humaid, François Bissuel, Patrick Biston, Laurent Bitker, Pablo Blanco-Schweizer,  
354 Mathieu Blot, Filomena Boccia, Debby Bogaert, François Bompart, Gareth Booth, Diogo Borges,  
355 Raphaël Borie, Jeannet Bos, Hans Martin Bosse, Elisabeth Botelho-Nevers, Lila Bouadma, Olivier  
356 Bouchaud, Sabelline Bouchez, Dounia Bouhmani, Damien Bouhour, Kévin Bouiller, Laurence Bouillet,  
357 Camille Bouisse, Anne-Sophie Boureau, Maude Bouscambert, Jason Bouziotis, Bianca Boxma,

358 Marielle Boyer-Besseyre, Maria Boylan, Cynthia Braga, Timo Brandenburger, Luca Brazzi, Dorothy  
359 Breen, Patrick Breen, Kathy Brickell, Nicolas Brozzi, Nina Buchtele, Christian Buesaquillo, Polina  
360 Bugaeva, Marielle Buisson, Erlina Burhan, Ingrid G. Bustos, Denis Butnaru, Sheila Cárcel, André  
361 Cabie, Susana Cabral, Eder Caceres, Mia Callahan, Kate Calligy, Jose Andres Calvache, João Camões,  
362 Valentine Campana, Paul Campbell, Cecilia Canepa, Mireia Cantero, Pauline Caraux-Paz, Filipa  
363 Cardoso, Filipe Cardoso, Sofia Cardoso, Simone Carelli, Nicolas Carlier, Gayle Carney, Chloe  
364 Carpenter, Marie-Christine Carret, François Martin Carrier, Gail Carson, Maire-Laure Casanova,  
365 Mariana Cascão, José Casimiro, Bailey Cassandra, Silvia Castañeda, Nidyanara Castanheira, Guylaine  
366 Castor-Alexandre, Henry Castrillón, Ivo Castro, Ana Catarino, François-Xavier Catherine, Roberta  
367 Cavalin, Giulio Giovanni Cavalli, Alexandros Cavayas, Adrian Ceccato, Minerva Cervantes-Gonzalez,  
368 Anissa Chair, Catherine Chakveatze, Adrienne Chan, Meera Chand, Julie Chas, Camille Chassin,  
369 Anjellica Chen, Yih-Sharng Chen, Matthew Pellan Cheng, Antoine Cheret, Thibault Chiarabini, Julian  
370 Chica, Catherine Chirouze, Davide Chiumello, Hwa Jin Cho, Sung Min Cho, Bernard Cholley, Jose  
371 Pedro Cidade, Jose Miguel Cisneros Herreros, Barbara Wanjiru Citarella, Anna Ciullo, Jennifer Clarke,  
372 Sara Clohisey, Cassidy Codan, Caitriona Cody, Alexandra Coelho, Gwenhaël Colin, Michael Collins,  
373 Sebastiano Maria Colombo, Pamela Combs, JP Connelly, Marie Connor, Anne Conrad, Sofia  
374 Contreras, Graham S. Cooke, Mary Copland, Hugues Cordel, Amanda Corley, Sarah Cormican, Sabine  
375 Cornelis, Arianne Joy Corpuz, Grégory Corvaisier, Camille Couffignal, Sandrine Couffin-Cadiergues,  
376 Roxane Courtois, Charles Crepy D'Orleans, Sabine Croonen, Gloria Crawl, Jonathan Crump, Claudina  
377 Cruz, Marc Csete, Alberto Cucino, Caroline Cullen, Matthew Cummings, Gerard Curley, Elodie Curlier,  
378 Paula Custodio, Frédérick D'Aragon, Ana Da Silva Filipe, Charlene Da Silveira, Eric D'Ortenzio, Al-  
379 Awwab Dabaliz, Andrew B. Dagens, Heidi Dalton, Jo Dalton, Nick Daneman, Emmanuelle A. Dankwa,  
380 Jorge Dantas, Nathalie De Castro, Diego De Mendoza, Rafael Freitas De Oliveira França, Rosanna De  
381 Rosa, Thushan De Silva, Peter De Vries, David Dean, Marie-Pierre Debray, William Dechert, Lauren  
382 Deconninck, Romain Decours, Isabelle Delacroix, Karen Delavigne, Ionna Deligiannis, Andrea  
383 Dell'amore, Pierre Delobel, Elisa Demonchy, Emmanuelle Denis, Dominique Deplanque, Dominique



384 Deplanque, Pieter Depuydt, Mehul Desai, Diane Descamps, Mathilde Desvallée, Santi Rahayu  
385 Dewayanti, Alpha Diallo, Sylvain Diamantis, André Dias, Juan Jose Diaz Diaz, Rodrigo Diaz, Kévin  
386 Didier, Jean-Luc Diehl, Wim Dieperink, Jérôme Dimet, Vincent Dinot, Alphonsine Diouf, Yael Dishon,  
387 Félix Djossou, Annemarie B. Docherty, Andy Dong, Christl A. Donnelly, Maria Donnelly, Chloe  
388 Donohue, Céline Dorival, James Joshua Douglas, Renee Douma, Nathalie Dournon, Triona Downer,  
389 Mark Downing, Tom Drake, Vincent Dubee, François Dubos, Alexandra Ducancelle, Susanne  
390 Dudman, Jake Dunning, Emanuele Durante Mangoni, Silvia Duranti, Lucian Durham III, Bertrand  
391 Dussol, Xavier Duval, Anne Margarita Dyrhol-Riise, Carla Eira, José Ernesto Vidal, Mohammed El  
392 Sanharawi, Subbarao Elapavaluru, Brigitte Elharrar, Natalie Elkheir, Jacobien Ellerbroek, Rachael Ellis,  
393 Philippine Eloy, Tarek Elshazly, Isabelle Enderle, Ilka Engelmann, Vincent Enouf, Olivier Epaulard,  
394 Mariano Esperatti, Hélène Esperou, Marina Esposito-Farese, João Estevão, Manuel Etienne, Manuel  
395 Etienne, Nadia Ettalhaoui, Anna Greti Everding, Mirjam Evers, Isabelle Fabre, Amna Faheem,  
396 Arabella Fahy, Cameron J. Fairfield, Pedro Faria, Nataly Farshait, Arie Zainul Fatoni, Karine Faure,  
397 Mohamed Fayed, Niamh Feely, Jorge Fernandes, Marília Fernandes, Susana Fernandes, Joana  
398 Ferrão, Eglantine Ferrand Devouge, Mário Ferraz, Benigno Ferreira, Ricard Ferrer-Roca, Claudia  
399 Figueiredo-Mello, Clara Fleteau, Tom Fletcher, Letizia Lucia Florio, Claire Foley, Victor Fomin, Claudio  
400 Duarte Fonseca, Tatiana Fonseca, Patricia Fontela, Simon Forsyth, Giuseppe Foti, Erwan Fourn, Rob  
401 Fowler, Diego Franch-Llasat, Christophe Fraser, John Fraser, Marcela Vieira Freire, Ana Freitas  
402 Ribeiro, Caren Friedrich, Stéphane Fry, Nora Fuentes, Masahiro Fukuda, Joan Gómez-Junyent,  
403 Valérie Gaborieau, Benoît Gachet, Rostane Gaci, Massimo Gagliardi, Jean-Charles Gagnard,  
404 Amandine Gagneux-Brunon, Sérgio Gaião, Phil Gallagher, Elena Gallego Curto, Carrol Gamble, Arthur  
405 Garan, Esteban Garcia-Gallo, Rebekha Garcia, Denis Garot, Valérie Garrait, Nathalie Gault, Aisling  
406 Gavin, Alexandre Gaymard, Johannes Gebauer, Louis Gerbaud Morlaes, Nuno Germano, Jade Ghosn,  
407 Marco Giani, Carlo Giaquinto, Jess Gibson, Tristan Gigante, Morgane Gilg, Guillermo Giordano,  
408 Michelle Girvan, Valérie Gissot, Gezy Giwangkancana, Daniel Glikman, Petr Glybochko, Eric Gnall,  
409 Geraldine Goco, François Goehringer, Siri Goepel, Jean-Christophe Goffard, Jonathan Golob, Isabelle

410 Gorenne, Cécile Goujard, Tiphaine Goulenok, Margarite Grable, Edward Wilson Grandin, Pascal  
411 Granier, Giacomo Grasselli, Christopher A. Green, William Greenhalf, Segolène Greffe, Domenico  
412 Luca Grieco, Matthew Griffee, Fiona Griffiths, Ioana Grigoras, Albert Groenendijk, Anja Grosse  
413 Lordemann, Heidi Gruner, Yusing Gu, Jérémie Guedj, Dewi Guellec, Anne-Marie Guerguerian,  
414 Daniela Guerreiro, Romain Guery, Anne Guillaumot, Laurent Guilleminault, Thomas Guimard, Daniel  
415 Haber, Sheeba Hakak, Matthew Hall, Sophie Halpin, Ansley Hamer, Rebecca Hamidfar, Terese  
416 Hammond, Hayley Hardwick, Kristen Harley, Ewen M. Harrison, Janet Harrison, Leanne Hays, Jan  
417 Heerman, Lars Heggelund, Ross Hendry, Martina Hennessy, Aquiles Henriquez-Trujillo, Maxime  
418 Hentzien, Jaime Hernandez-Montfort, Astarini Hidayah, Dawn Higgins, Eibhilin Higgins, Samuel  
419 Hinton, Ana Hipólito -Reis, Hiroaki Hiraiwa, Julian A. Hiscox, Antonia Ying Wai Ho, Alexandre Hochtin,  
420 Isabelle Hoffmann, Oscar Hoiting, Rebecca Holt, Jan Cato Holter, Peter Horby, Juan Pablo Horcajada,  
421 Koji Hoshino, Kota Hoshino, Catherine L. Hough, Jimmy Ming-Yang Hsu, Jean-Sébastien Hulot,  
422 Samreen Ijaz, Hajnal-Gabriela Illes, Hugo Inácio, Carmen Infante Dominguez, Elias Iosifidis, Lacey  
423 Irvine, Sarah Isgett, Tiago Isidoro, Margaux Isnard, Junji Itai, Daniel Ivulich, Salma Jaafoura, Julien  
424 Jabot, Clare Jackson, Nina Jamieson, Stéphane Jaureguiberry, Jeffrey Javidfar, Zabbe Jean-Benoît,  
425 Florence Jego, Synne Jenum, Ruth Jimbo Sotomayor, Ruth Noemí Jorge García, Cédric Joseph, Mark  
426 Joseph, Philippe Jovet, Hanna Jung, Ouifiya Kafif, Florentia Kaguelidou, Sabina Kali, Smaragdi  
427 Kalomoiri, Darshana Hewa Kandamby, Chris Kandel, Ravi Kant, Christiana Kartsonaki, Daisuke  
428 Kasugai, Kevin Katz, Simreen Kaur Johal, Sean Keating, Andrea Kelly, Sadie Kelly, Lisa Kennedy,  
429 Kalynn Kennon, Younes Kerroumi, Evelyne Kestelyn, Imrana Khalid, Antoine Khalil, Coralie Khan,  
430 Irfan Khan, Michelle E Kho, Saye Khoo, Yuri Kida, Peter Kiiza, Anders Benjamin Kildal, Antoine  
431 Kimmoun, Detlef Kindgen-Milles, Nobuya Kitamura, Paul Klenerman, Gry Kloumann Bekken, Stephen  
432 Knight, Robin Kobbe, Malte Kohns Vasconcelos, Volkan Korten, Caroline Kosgei, Karolina Krawczyk,  
433 Pavan Kumar Vecham, Deepali Kumar, Ethan Kurtzman, Demetrios Kutsogiannis, Konstantinos  
434 Kyriakoulis, Erwan L'her, Marie Lachatre, Marie Lacoste, John G Laffey, Marie Lagrange, Fabrice  
435 Laine, Marc Lambert, François Lamontagne, Marie Langelot-Richard, Eka Yudha Lantang, Marina

436 Lanza, Cédric Laouénan, Samira Laribi, Delphine Lariviere, Odile Launay, Yoan Lavie-Badie, Andrew  
437 Law, Clément Le Bihan, Cyril Le Bris, Eve Le Coustumier, Georges Le Falher, Sylvie Le Gac, Quentin Le  
438 Hingrat, Marion Le Maréchal, Soizic Le Mestre, Vincent Le Moing, Hervé Le Nagard, Paul Le Turnier,  
439 Rafael León, Minh Le, Marta Leal Santos, Ema Leal, James Lee, Su Hwan Lee, Todd Lee, Gary  
440 Leeming, Bénédicte Lefebvre, Laurent Lefebvre, Benjamin Lefevre, François Lellouche, Adrien  
441 Lemaigen, Véronique Lemee, Gretchen Lemmink, Michela Leone, Quentin Lepiller, François-Xavier  
442 Lescure, Olivier Lesens, Mathieu Lesouhaitier, Claire Levy-Marchal, Bruno Levy, Yves Levy, Gianluigi  
443 Li Bassi, Janet Liang, Wei Shen Lim, Bruno Lina, Andreas Lind, Guillaume Lingas, Sylvie Lion-Daolio,  
444 Keibun Liu, Antonio Loforte, Navy Lolong, Diogo Lopes, Dalia Lopez-Colon, Paul Loubet, Jean  
445 Christophe Lucet, Carlos M. Luna, Olguta Lungu, Liem Luong, Dominique Luton, Ruth Lyons, Fredrik  
446 Müller, Karl Erik Müller, Olavi Maasikas, Sarah Macdonald, Moïse Machado, Gabrielle Macheda, Juan  
447 Macias Sanchez, Jai Madhok, Rafael Mahieu, Sophie Mahy, Lars Siegfried Maier, Mylène Maillet,  
448 Thomas Maitre, Maximilian Malfertheiner, Nadia Malik, Fernando Maltez, Denis Malvy, Marina  
449 Mambert, Victoria Manda, Jose M. Mandei, Edmund Manning, Aldric Manuel, Ceila Maria Sant`Ana  
450 Malaque, Flávio Marino, Carolline De Araújo Mariz, Charbel Maroun Eid, Ana Marques, Catherine  
451 Marquis, Brian Marsh, Laura Marsh, John Marshall, Celina Turchi Martelli, Guillaume Martin-Blondel,  
452 Ignacio Martin-Loeches, Alejandro Martin-Quiros, Dori-Ann Martin, Emily Martin, Martin Martinot,  
453 Caroline Martins Rego, Ana Martins, João Martins, Gennaro Martucci, Eva Miranda Marwali, Juan  
454 Fernando Masa Jimenez, David Maslove, Sabina Mason, Moshe Matan, Daniel Mathieu, Mathieu  
455 Mattei, Romans Matulevics, Laurence Maulin, Natalie Mc Evoy, Aine McCarthy, Anne McCarthy,  
456 Colin McCloskey, Rachael McConnochie, Sherry McDermott, Sarah McDonald, Samuel McElwee,  
457 Natalie McEvoy, Allison McGeer, Niki McGuinness, Kenneth A. McLean, Bairbre McNicholas, Edel  
458 Meaney, Cécile Mear-Passard, Maggie Mechlin, Ferruccio Mele, Kusum Menon, France Mentré,  
459 Alexander J. Mentzer, Noémie Mercier, Antoine Merckx, Blake Mergler, Laura Merson, António  
460 Mesquita, Agnès Meybeck, Alison M. Meynert, Vanina Meyssonier, Amina Meziane, Medhi Mezidi,  
461 Céline Michelangeli, Vladislav Mihnovitš, Hugo Miranda Maldonado, Mary Mone, Asma Moin, David

462 Molina, Elena Molinos, Agostinho Monteiro, Claudia Montes, Giorgia Montrucchio, Sarah Moore,  
463 Shona C. Moore, Lina Morales-Cely, Lucia Moro, Diego Rolando Morocho Tutillo, Ana Motos, Hugo  
464 Mouquet, Clara Mouton Perrot, Julien Moyet, Jimmy Mullaert, Daniel Munblit, Derek Murphy,  
465 Marlène Murriss, Dimitra Melia Myrodi, Yohan N'guyen, Nadège Neant, Holger Neb, Nikita A  
466 Nekliudov, Raul Neto, Emily Neumann, Bernardo Neves, Pauline Yeung Ng, Wing Yiu Ng, Orna Ni  
467 Choileain, Alistair Nichol, Stephanie Nonas, Marion Noret, Lisa Norman, Alessandra Notari, Mahdad  
468 Noursadeghi, Karolina Nowicka, Saad Nseir, Jose I Nunez, Elsa Nyamankolly, Max O'Donnell, Katie  
469 O'Hearn, Conar O'Neil, Giovanna Occhipinti, Tawnya Ogston, Takayuki Ogura, Tak-Hyuk Oh,  
470 Shinichiro Ohshimo, Budha Charan Singh Oinam, Ana Pinho Oliveira, João Oliveira, Piero Olliaro,  
471 David S. Y. Ong, Wilna Oosthuyzen, Peter J.M. Openshaw, Claudia Milena Orozco-Chamorro, Andrés  
472 Orquera, Javier Osatnik, Nadia Ouamara, Rachida Ouissa, Clark Owyang, Eric Oziol, Diana Póvoas,  
473 Maïder Pagadoy, Justine Pages, Mario Palacios, Massimo Palmarini, Giovanna Panarello, Prasan  
474 Kumar Panda, Mauro Panigada, Nathalie Pansu, Aurélie Papadopoulos, Briseida Parra, Jérémie  
475 Pasquier, Fabian Patauner, Luís Patrão, Christelle Paul, Mical Paul, Jorge Paulos, William A. Paxton,  
476 Jean-François Payen, India Pearse, Giles J Peek, Florent Peelman, Nathan Peiffer-Smadja, Vincent  
477 Peigne, Mare Pejkovska, Ithan D. Peltan, Rui Pereira, Daniel Perez, Thomas Perpoint, Antonio  
478 Pesenti, Lenka Petroušová, Ventzislava Petrov-Sanchez, Gilles Peytavin, Scott Pharand, Michael  
479 Piagnerelli, Walter Picard, Olivier Picone, Marie Piel-Julian, Carola Pierobon, Carlos Pimentel, Lionel  
480 Piroth, Riinu Pius, Simone Piva, Laurent Plantier, Daniel Plotkin, Julien Poissy, Maria Pokorska-  
481 Spiewak, Sergio Poli, Georgios Pollakis, Jolanta Popielska, Douwe F. Postma, Pedro Povoá, Jeff Powis,  
482 Sofia Prapa, Christian Prebensen, Jean-Charles Preiser, Vincent Prestre, Nicholas Price, Anton  
483 Prinssen, Mark G. Pritchard, Lúcia Proença, Oriane Puéchal, Gregory Purcell, Luisa Quesada, Else  
484 Quist-Paulsen, Mohammed Quraishi, Indrek Rätsep, Bernhard Rössler, Christian Rabaud, Marie  
485 Rafiq, Gabrielle Ragazzo, Fernando Rainieri, Nagarajan Ramakrishnan, Kollengode Ramanathan,  
486 Blandine Rammaert, Christophe Rapp, Menaldi Rasmin, Cornelius Rau, Stanislas Rebaudet, Sarah  
487 Redl, Brenda Reeve, Liadain Reid, Renato Reis, Jonathan Remppis, Martine Remy, Hanna Renk,

488 Liliana Resende, Anne-Sophie Resseguier, Matthieu Revest, Oleksa Rewa, Luis Felipe Reyes, David  
489 Richardson, Denise Richardson, Laurent Richier, Jordi Riera, Ana Lúcia Rios, Asgar Rishu, Patrick  
490 Rispal, Karine Risso, Maria Angelica Rivera Nuñez, Nicholas Rizer, André Roberto, Stephanie Roberts,  
491 David L. Robertson, Olivier Robineau, Ferran Roche-Campo, Paola Rodari, Simão Rodeia, Julia  
492 Rodriguez Abreu, Emmanuel Roilides, Amanda Rojek, Juliette Romaru, Roberto Roncon-Albuquerque  
493 Jr, Mélanie Roriz, Manuel Rosa-Calatrava, Michael Rose, Dorothea Rosenberger, Andrea Rossanese,  
494 Bénédicte Rossignol, Patrick Rossignol, Carine Roy, Benoît Roze, Clark D. Russell, Steffi Ryckaert,  
495 Aleksander Rygh Holten, Xavier Sánchez Choez, Isabela Saba, Musharaf Sadat, Nadia Saidani,  
496 Leonardo Salazar, Gabriele Sales, Stéphane Sallaberry, Hélène Salvator, Angel Sanchez-Miralles,  
497 Olivier Sanchez, Vanessa Sancho-Shimizu, Gyan Sandhu, Oana Sandulescu, Marlene Santos, Shirley  
498 Sarfo-Mensah, Benjamine Sarton, Egle Saviciute, Parthena Savvidou, Joshua Scarsbrook, Tjard  
499 Schermer, Arnaud Scherpereel, Marion Schneider, Stephan Schroll, Michael Schwameis, James Scott-  
500 Brown, Janet T. Scott, Nicholas Sedillot, Tamara Seitz, Caroline Semaille, Malcolm G. Semple, Eric  
501 Senneville, Filipa Sequeira, Tânia Sequeira, Ellen Shadowitz, Mohammad Shamsah, Pratima Sharma,  
502 Catherine A. Shaw, Victoria Shaw, Nisreen Shiban, Nobuaki Shime, Hiroaki Shimizu, Keiki Shimizu,  
503 Sally Shrapnel, Hoi Ping Shum, Nassima Si Mohammed, Louise Sigfrid, Catarina Silva, Maria Joao  
504 Silva, Wai Ching Sin, Vegard Skogen, Sue Smith, Benjamin Smood, Michelle Smyth, Morgane  
505 Snacken, Dominic So, Monserrat Solis, Joshua Solomon, Tom Solomon, Emily Somers, Agnès  
506 Sommet, Myung Jin Song, Rima Song, Tae Song, Michael Sonntagbauer, Edouard Soum, Maria Sousa  
507 Uva, Marta Sousa, Vicente Souza-Dantas, Alexandra Sperry, Shiranee Sriskandan, Thomas  
508 Staudinger, Stephanie-Susanne Stecher, Ymkje Stienstra, Birgitte Stiksrud, Adrian Streinu-Cercel,  
509 Anca Streinu-Cercel, Samantha Strudwick, Ami Stuart, David Stuart, Asfia Sultana, Charlotte  
510 Summers, Magdalena Surovcová Andrey A Svistunov, Konstantinos Syrigos, Jaques Sztajnbok,  
511 Konstanty Szuldrzynski, François Téoulé, Shirin Tabrizi, Lysa Tagherset, Ewa Talarek, Sara Taleb,  
512 Jelmer Talsma, Le Van Tan, Hiroyuki Tanaka, Taku Tanaka, Hayato Taniguchi, Coralie Tardivon, Pierre  
513 Tattevin, M Azhari Taufik, Richard S. Tedder, João Teixeira, Marie-Capucine Tellier, Pleun Terpstra,

514 Olivier Terrier, Nicolas Terzi, Hubert Tessier-Grenier, Vincent Thibault, Simon-Djamel Thiberville,  
515 Benoît Thill, A.A. Roger Thompson, Shaun Thompson, David Thomson, Emma C. Thomson, Duong  
516 Bich Thuy, Ryan S. Thwaites, Peter S. Timashev, Jean-François Timsit, Bharath Kumar Tirupakuzhi  
517 Vijayaraghavan, Maria Toki, Kristian Tonby, Rosario Maria Torres Santos-Olmo, Antoni Torres,  
518 Margarida Torres, Théo Trioux, Huynh Trung Trieu, Cécile Tromeur, Ioannis Trontzas, Jonathan  
519 Troost, Tiffany Trouillon, Christelle Tual, Sarah Tubiana, Helen Tuite, Lance C.W. Turtle, Pawel  
520 Twardowski, Makoto Uchiyama, Roman Ullrich, Alberto Uribe, Asad Usman, Luís Val-Flores, Stijn Van  
521 De Velde, Marcel Van Den Berge, Machteld Van Der Feltz, Nicky Van Der Vekens, Peter Van Der  
522 Voort, Sylvie Van Der Werf, Marlice Van Dyk, Laura Van Gulik, Jarne Van Hattem, Steven Van  
523 Lelyveld, Carolien Van Netten, Noémie Vanel, Henk Vanoverschelde, Charline Vauchy, Aurélie  
524 Veislinger, Jorge Velazco, Sara Ventura, Annelies Verbon, César Vieira, Joy Ann Villanueva, Judit  
525 Villar, Pierre-Marc Villeneuve, Andrea Villoldo, Nguyen Van Vinh Chau, Benoit Visseaux, Hannah  
526 Visser, Aapeli Vuorinen, Fanny Vuotto, Chih-Hsien Wang, Jia Wei, Katharina Weil, Sanne Wesselius,  
527 Murray Wham, Bryan Whelan, Nicole White, Aurélie Wiedemann, Keith Wille, Evert-Jan Wils, Ioannis  
528 Xynogalas, Jacky Y Suen, Sophie Yacoub, Masaki Yamazaki, Yazdan Yazdanpanah, Cécile Yelnik,  
529 Stephanie Yerkovich, Toshiki Yokoyama, Hodane Yonis, Paul Young, Saptadi Yulianto, Marion Zabbe,  
530 Kai Zacharowski, Maram Zahran, Maria Zambon, Alberto Zanella, Konrad Zawadka, Hiba Zayyad,  
531 Alexander Zoufaly, David Zucman; The PETAL Network Investigators, The Western Australian  
532 Covid-19 Research Response.

## 533 [References](#)

- 534 1. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L,  
535 Emperador D, Ditttrich S, Domen J, Horn SRA, Van den Bruel A. Signs and symptoms to determine if a  
536 patient presenting in primary care or hospital outpatient settings has COVID-19 disease. *Cochrane*  
537 *Database Syst Rev* 2020: 7(7): Cd013665.
- 538 2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng  
539 G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu  
540 Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS.  
541 Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020: 382(18): 1708-1720.
- 542 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J,  
543 Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q,

- 544 Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.  
545 *Lancet* 2020: 395(10223): 497-506.
- 546 4. Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, Liu XQ, Sang L, Chen RC, Tang CL, Wang T,  
547 Wang W, He QH, Chen ZS, Wong SS, Zanin M, Liu J, Xu X, Huang J, Li JF, Ou LM, Cheng B, Xiong S, Xie  
548 ZH, Ni ZY, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li  
549 G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX.  
550 Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei  
551 (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. *Eur Respir J* 2020:  
552 55(6): 2000562.
- 553 5. Wang G, Chen W, Jin X, Chen YP. Description of COVID-19 cases along with the measures  
554 taken on prevention and control in Zhejiang, China. *J Med Virol* 2020.
- 555 6. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C,  
556 Ridolfo AL, Rizzardini G, Antinori S, Galli M. Self-reported olfactory and taste disorders in patients  
557 with severe acute respiratory coronavirus 2 infection: A cross-sectional study. *Clin Infect Dis* 2020:  
558 71(15): 889-890.
- 559 7. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory  
560 dysfunction and COVID-19 in patients presenting with influenza-like symptoms. *Int Forum Allergy  
561 Rhinol* 2020: 10(7): 806-813.
- 562 8. Manoharan L, Cattrall JWS, Harris C, Newell K, Thomson B, Pritchard MG, Bannister PG,  
563 Sigfrid L, Solomon T, Horby PW, Carson G, Olliaro PL. Early clinical characteristics of Covid-19:  
564 scoping review. *MedRxiv* 2020: 2020.07.31.20165738 [Preprint]. August 4, 2020 [cited 7 August  
565 2020]. .
- 566 9. World Health Organization. WHO COVID-19: Case definitions [WHO/2019-  
567 nCoV/Surveillance\_Case\_Definition/2020.1]. Geneva, Switzerland: World Health Organization; 2020.
- 568 10. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) 2020  
569 interim case definition. 2020 [cited 2020 9 November]; Available from:  
570 <https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/>
- 571 11. Public Health England. COVID19: investigation and initial clinical management of possible  
572 cases. 2020 [cited 2020 9 November]; Available from:  
573 <https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection>
- 574 12. European Centre for Disease Prevention and Control. Case definition for coronavirus disease  
575 2019 (COVID-19), as of 29 May 2020. 2020 [cited 2020 9 November]; Available from:  
576 <https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition>
- 577 13. International Severe Acute Respiratory and Emerging Infection Consortium, World Health  
578 Organization. ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections, version  
579 3.2: ISARIC; 2020.
- 580 14. ISARIC clinical characterisation group. Global outbreak research: harmony not hegemony.  
581 *Lancet Infect Dis* 2020: 20(7): 770-772.
- 582 15. International Severe Acute Respiratory and Emerging Infection Consortium. COVID-19 CRF.  
583 2020 [cited 21 August 2020]; Available from: <https://isaric.org/research/covid-19-clinical-research-resources/covid-19-crf/>
- 584 16. ISARIC 4C. ISARIC 4C protocols. 2020 [cited 26 August 2020]; Available from:  
585 <https://isaric4c.net/protocols/>
- 586 17. COVID-19 Critical Care Consortium. COVID-19 Critical Care Consortium Trial Documents.  
587 2020 [cited 26 August 2020]; Available from: <https://www.elseo.org/COVID19/ECMOCARD.aspx>
- 588 18. Munblit D, Nekliudov NA, Bugaeva P, Blyuss O, Kislova M, Listovskaya E, Gamirova A,  
589 Shikhaleva A, Belyaev V, Timashev P, Warner JO, Comberati P, Apfelbacher C, Bezrukov E, Politov  
590 ME, Yavorovskiy A, Bulanova E, Tsareva N, Avdeev S, Kapustina VA, Pigolkin YI, Dankwa EA,  
591 Kartsonaki C, Pritchard MG, Victor F, Svistunov AA, Butnaru D, Glybochko P. StopCOVID cohort: An

- 595 observational study of 3,480 patients admitted to the Sechenov University hospital network in  
596 Moscow city for suspected COVID-19 infection. *Clin Infect Dis* 2020.
- 597 19. Larsen K, Merlo J. Appropriate assessment of neighborhood effects on individual health:  
598 integrating random and fixed effects in multilevel logistic regression. *Am J Epidemiol* 2005; 161(1):  
599 81-8.
- 600 20. World Bank. World Bank country and lending groups. 2020 [cited; Available from:  
601 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)  
602 [lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
- 603 21. Lauretani F, Ravazzoni G, Roberti MF, Longobucco Y, Adorni E, Grossi M, De Iorio A, La Porta  
604 U, Fazio C, Gallini E, Federici R, Salvi M, Ciarrocchi E, Rossi F, Bergamin M, Bussolati G, Grieco I,  
605 Broccoli F, Zucchini I, Ielo G, Morganti S, Artoni A, Arisi A, Tagliaferri S, Maggio M. Assessment and  
606 treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications.  
607 *Acta Biomed* 2020; 91(2): 150-168.
- 608 22. Jung YJ, Yoon JL, Kim HS, Lee AY, Kim MY, Cho JJ. Atypical clinical presentation of geriatric  
609 syndrome in elderly patients with pneumonia or coronary artery disease. *Ann Geriatr Med Res* 2018:  
610 21(4): 158-163.
- 611 23. Wester AL, Dunlop O, Melby KK, Dahle UR, Wyller TB. Age-related differences in symptoms,  
612 diagnosis and prognosis of bacteremia. *BMC Infect Dis* 2013; 13: 346.
- 613 24. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D,  
614 Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong  
615 GWK. SARS-CoV-2 Infection in Children. *N Engl J Med* 2020; 382(17): 1663-1665.
- 616 25. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better  
617 prognosis than adults. *Acta Paediatr* 2020; 109: 1088-1095.
- 618 26. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, Seth S, Egan C, Hardwick  
619 HE, Halpin S, Girvan M, Donohue C, Pritchard M, Patel LB, Ladhani S, Sigfrid L, Sinha IP, Olliaro PL,  
620 Nguyen-Van-Tam JS, Horby PW, Merson L, Carson G, Dunning J, Openshaw PJM, Baillie JK, Harrison  
621 EM, Docherty AB, Semple MG. Clinical characteristics of children and young people admitted to  
622 hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. *BMJ*  
623 2020; 370: m3249.
- 624 27. Millar JE, Neyton L, Seth S, Dunning J, Merson L, Murthy S, Russell CD, Keating S, Swets M,  
625 Sudre CH, Spector TD, Ourselin S, Steves CJ, Wolf J, Docherty AB, Harrison EM, Openshaw PJ, Semple  
626 MG, Baillie JK. Robust, reproducible clinical patterns in hospitalised patients with COVID-19. *MedRxiv*  
627 2020: 2020.08.14.20168088 [Preprint]. August 16, 2020 [cited 2 September 2020].
- 628 28. Sierpiński R, Pinkas J, Jankowski M, Zgliczyński WS, Wierzba W, Gujski M, Szumowski Ł. Sex  
629 differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders in 1942  
630 nonhospitalized patients with coronavirus disease 2019 (COVID-19). *Pol Arch Intern Med* 2020;  
631 130(6): 501-505.

632

633



634 **Tables**

635 **Table 1. Patient demographics**

Variable*	Overall n = 601109	Sex		P-value
		Female n = 251468	Male n = 349641	
Age (years): median [IQR]	70 [54, 82]	72 [55, 83]	68 [54, 80]	<0.001
Age bands (years)				<0.001
0–10	514 (0.9)	221 (0.9)	293 (0.8)	
10–20	522 (0.9)	221 (0.9)	301 (0.9)	
20–30	1972 (3.3)	872 (3.4)	1100 (3.2)	
30–40	3209 (5.3)	1450 (5.7)	1759 (5.1)	
40–50	5013 (8.3)	1966 (7.7)	3047 (8.8)	
50–60	8581 (14.3)	3280 (12.9)	5301 (15.3)	
60–70	9874 (16.4)	3701 (14.5)	6173 (17.8)	
70–80	12333 (20.5)	4916 (19.3)	7417 (21.4)	
80–90	13483 (22.4)	6196 (24.3)	7287 (21.0)	
>=90	4608 (7.7)	2645 (10.4)	1963 (5.7)	
Region†				<0.001
East Asia & Pacific	3252 (5.4)	1117 (4.4)	2135 (6.2)	
Europe & Central Asia	55401 (92.2)	23749 (93.3)	31652 (91.4)	
Latin America & Caribbean	162 (0.3)	67 (0.3)	95 (0.3)	
Middle East & North Africa	91 (0.2)	35 (0.1)	56 (0.2)	
North America	926 (1.5)	413 (1.6)	513 (1.5)	
South Asia	267 (0.4)	83 (0.3)	184 (0.5)	
Sub-Saharan Africa	10 (0.0)	4 (0.0)	6 (0.0)	

It is made available under a [CC-BY-ND 4.0 International license](#) .

Country income classification <sup>†</sup>				<0.001
High income	54836 (91.2)	23420 (92.0)	31416 (90.7)	
Upper middle income	5003 (8.3)	1964 (7.7)	3039 (8.8)	
Lower middle or low income	270 (0.4)	84 (0.3)	185 (0.5)	

---

IQR, interquartile range

\* Data are number (percent within columns) unless specified otherwise

† According to World Bank classification [20]

---

636

637

638

639 **Table 2. Symptoms at presentation to hospital with COVID-19**

Variable *	Sex				
	Overall n = 602109	Female n = 252468	Male n = 342641	P- value	Missing data <sup>†</sup>
Fever	41067 (68.7)	16649 (65.7)	24418 (70.8)	<0.001	291 (0.5)
Cough	40898 (68.5)	16683 (65.9)	24215 (70.4)	<0.001	401 (0.7)
Shortness of breath	37577 (65.8)	15450 (64.0)	22127 (67.2)	<0.001	3024 (5.0)
Fatigue	23319 (46.4)	9889 (46.3)	13430 (46.5)	0.622	9893 (16.5)
Confusion	13732 (27.3)	6108 (28.2)	7624 (26.5)	<0.001	9730 (16.2)
Muscle pains	9472 (20.1)	3952 (19.8)	5520 (20.3)	0.137	12980 (21.6)
Diarrhoea	10061 (19.1)	4565 (20.4)	5496 (18.2)	<0.001	7544 (12.6)
Nausea and vomiting	9891 (18.8)	5099 (22.8)	4792 (15.8)	<0.001	7464 (12.4)
Anorexia	613 (15.7)	243 (14.3)	370 (16.8)	0.038	56202 (93.5)
Severe dehydration	3451 (14.8)	1562 (15.4)	1889 (14.3)	0.027	36756 (61.1)
Chest pain	6953 (13.6)	3084 (14.2)	3869 (13.1)	0.001	8953 (14.9)
Headache	6154 (13.0)	2830 (14.1)	3324 (12.2)	<0.001	12796 (21.3)
Sore throat	4880 (10.5)	2135 (10.8)	2745 (10.3)	0.097	13836 (23.0)
Abdominal pain	5305 (10.4)	2597 (12.0)	2708 (9.2)	<0.001	9015 (15.0)
Wheeze	3845 (7.9)	1790 (8.6)	2055 (7.4)	<0.001	11390 (18.9)
Altered sense of taste	2011 (7.4)	924 (7.8)	1087 (7.1)	0.023	32830 (54.6)
Joint pains	3229 (7.1)	1459 (7.5)	1770 (6.8)	0.002	14587 (24.3)
Altered sense of smell	1733 (6.2)	819 (6.7)	914 (5.7)	0.001	31969 (53.2)
Rhinorrhoea	2382 (5.2)	1041 (5.3)	1341 (5.1)	0.264	14403 (24.0)
Unable to walk	220 (5.0)	83 (4.4)	137 (5.4)	0.141	55668 (92.6)
Skin ulcer	978 (2.3)	489 (2.7)	489 (2.1)	<0.001	18486 (30.8)

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/) .

Haemorrhage	993 (2.0)	429 (2.0)	564 (2.0)	0.695	9902 (16.5)
Lower chest wall					
indrawing	688 (1.6)	235 (1.3)	453 (1.9)	<0.001	17887 (29.8)
Seizure	775 (1.6)	352 (1.7)	423 (1.5)	0.169	12055 (20.1)
Rash	694 (1.4)	287 (1.4)	407 (1.5)	0.555	11400 (19.0)
Lymphadenopathy	307 (0.7)	147 (0.8)	160 (0.6)	0.099	15267 (25.4)
Conjunctivitis	251 (0.5)	111 (0.5)	140 (0.5)	0.642	12491 (20.8)
Ear pain	201 (0.5)	107 (0.6)	94 (0.4)	0.003	19036 (31.7)
<hr/>					
<i>Composite categories</i>					3446 (5.7) <sup>‡</sup>
Fever and cough; or at least three of fever, cough, fatigue, headache, muscle pains, sore throat, rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion					
	40911 (72.2)	17014 (71.0)	23897 (73.1)	<0.001	
Cough or shortness of breath; or at least two of fever, muscle pains, headache, or sore throat					
	48464 (85.5)	20103 (83.9)	28361 (86.7)	<0.001	
Cough or fever					
	48494 (85.6)	19973 (83.3)	28521 (87.2)	<0.001	
At least one of cough, fever or shortness of breath					
	52041 (91.8)	21607 (90.2)	30434 (93.1)	<0.001	

\* Data are number (percent of patients with non-missing data within columns) unless specified otherwise

† Number (percent of all patients)

‡ Patients missing any of cough, fever or shortness of breath are omitted from the composite categories

641 **Table 3. Symptoms reported for patients meeting none of the clinical case definitions**

642

Symptom *	Age group (years)											Missing data
	Overall n = 4622	0– n = 44	10– n = 100	20– n = 269	30– n = 256	40– n = 217	50– n = 309	60– n = 484	70– n = 922	80– n = 1406	90– n = 615	
Confusion	1917 (46.9)	4 (9.8)	2 (4.2)	7 (6.2)	9 (5.8)	23 (14.1)	57 (21.3)	155 (35.1)	474 (52.8)	785 (57.7)	401 (66.4)	531 (11.5)
Fatigue	1245 (29.1)	9 (23.1)	10 (10.3)	30 (11.3)	37 (15.2)	42 (20.7)	83 (28.1)	148 (33.2)	284 (33.3)	444 (34.4)	158 (28.6)	340 (7.4)
Severe dehydration	472 (22.6)	1 (5.0)	1 (4.3)	4 (8.3)	2 (2.9)	7 (11.3)	18 (13.1)	40 (18.0)	110 (24.8)	201 (27.1)	88 (27.6)	2535 (54.8)
Nausea and vomiting	995 (22.2)	19 (44.2)	24 (24.0)	44 (16.4)	59 (23.4)	77 (36.0)	94 (31.2)	127 (27.1)	210 (23.4)	245 (18.3)	96 (16.2)	145 (3.1)
Abdominal pain	812 (18.5)	9 (22.5)	22 (22.4)	52 (19.5)	67 (26.6)	54 (25.8)	80 (27.0)	107 (23.1)	173 (19.6)	184 (13.9)	64 (11.2)	223 (4.8)
Diarrhoea	612 (13.8)	8 (19.0)	6 (6.1)	26 (9.7)	25 (10.0)	31 (14.8)	46 (15.5)	94 (20.3)	136 (15.2)	177 (13.4)	63 (10.9)	201 (4.3)
Headache	347 (8.3)	2 (6.1)	13 (13.4)	48 (18.4)	39 (16.0)	47 (23.2)	32 (11.0)	45 (10.3)	52 (6.3)	47 (3.8)	22 (4.1)	454 (9.8)
Muscle pains	301 (7.3)	4 (11.8)	5 (5.2)	19 (7.2)	28 (11.5)	24 (12.1)	27 (9.4)	39 (9.0)	54 (6.6)	65 (5.3)	36 (6.8)	482 (10.4)
Joint pains	293 (7.1)	3 (9.1)	4 (4.2)	9 (3.4)	8 (3.3)	13 (6.5)	14 (4.9)	27 (6.2)	49 (6.0)	109 (8.8)	57 (10.7)	473 (10.2)
Chest pain	299 (6.8)	0 (0.0)	1 (1.0)	12 (4.5)	15 (6.0)	21 (9.8)	44 (14.6)	49 (10.6)	51 (5.8)	79 (6.0)	27 (4.7)	209 (4.5)
Sore throat	277 (6.7)	4 (11.1)	24 (25.0)	83 (31.7)	62 (25.1)	39 (19.3)	16 (5.5)	18 (4.1)	17 (2.1)	9 (0.7)	5 (1.0)	460 (10.0)
Haemorrhage	233 (5.5)	0 (0.0)	1 (1.1)	5 (2.1)	10 (4.3)	12 (6.0)	14 (4.8)	22 (4.9)	45 (5.2)	84 (6.5)	40 (7.0)	347 (7.5)
Altered sense of smell	149 (4.9)	1 (4.0)	20 (24.1)	48 (22.7)	30 (16.0)	17 (11.4)	11 (5.1)	9 (2.8)	4 (0.7)	9 (1.0)	0 (0.0)	1584 (34.3)
Rhinorrhoea	188 (4.5)	3 (7.5)	28 (29.2)	58 (22.1)	43 (17.6)	23 (11.4)	14 (4.8)	7 (1.6)	6 (0.7)	2 (0.2)	4 (0.7)	476 (10.3)
Skin ulcer	153 (4.2)	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	9 (3.7)	13 (3.3)	43 (5.3)	51 (4.1)	34 (6.2)	982 (21.2)
Seizure	152 (3.8)	5 (11.6)	3 (6.2)	3 (2.7)	6 (3.9)	11 (6.7)	16 (6.1)	22 (5.1)	34 (3.9)	39 (3.0)	13 (2.3)	659 (14.3)
Altered sense of taste	101 (3.3)	1 (4.5)	10 (12.0)	27 (13.0)	15 (8.1)	10 (6.8)	3 (1.4)	7 (2.2)	11 (2.0)	13 (1.5)	4 (1.0)	1602 (34.7)

Rash	78 (1.8)	5 (11.6)	3 (3.0)	2 (0.8)	1 (0.4)	4 (2.0)	5 (1.7)	17 (3.8)	18 (2.2)	15 (1.2)	8 (1.5)	384 (8.3)
Wheeze	53 (1.2)	0 (0.0)	0 (0.0)	1 (0.4)	1 (0.4)	0 (0.0)	3 (1.0)	6 (1.3)	8 (0.9)	22 (1.7)	12 (2.1)	296 (6.4)

\* Data are number (percent of patients with non-missing data within columns). Symptoms experienced by <25 individuals are omitted.

643

644

## 645 Figure legends

### 646 **Figure 1. Flow of participants in this analysis.**

647 4C, Coronavirus Clinical Characterisation Consortium; CCC, Critical Care Consortium; ISARIC,  
648 International Severe Acute Respiratory and emerging Infection Consortium; REDCap, Research  
649 Electronic Data Capture; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.

650

651

### 652 **Figure 2. Age-specific prevalence of symptoms at hospital admission.**

653 Dark blue bars show symptom present, maroon bars show symptom absent, pale grey bars show  
654 missing data.

655

### 656 **Figure 3. Proportions meeting clinical criteria at hospital admission stratified by 10-year age band.**

657 Black boxes show the proportion of individuals, with error bars showing 95% confidence intervals  
658 calculated using the Clopper–Pearson method. The size of each box is inversely proportional to the  
659 variance, so larger boxes indicate greater certainty. Grey boxes with 95% confidence intervals show  
660 the proportions in the sensitivity analysis excluding patients recruited in the United Kingdom. In  
661 panel A, the three symptoms are from the list of fever, cough, fatigue, headache, myalgia, sore  
662 throat, rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion; in panel B  
663 the two symptoms are from the list fever, myalgia, headache, and sore throat. Patients with missing  
664 data for cough, fever or shortness of breath are excluded from all four plots.

665

### 666 **Figure 4. Odds of symptoms among patients admitted to hospital with COVID-19, stratified by age 667 and sex.**

668 Each plot is the result of a logistic regression with a symptom as an outcome. Fixed effects of age in  
669 ten-year bands (baseline group 50–60 years) and sex are shown in black boxes with 95% confidence

670 intervals. The size of each square is inversely proportional to the variance of the log odds ratio, so  
671 larger boxes indicate greater certainty. Clustering by country is included as a random intercept and  
672 heterogeneity is depicted by circles showing the median odds ratio.

673

674

675 **Figure 5. Age- and sex- specific odds of meeting clinical definitions among patients admitted to**  
676 **hospital with COVID-19, stratified by age and sex.**

677 Each plot is the result of a logistic regression with a composite group of symptoms as an outcome.

678 Fixed effects of age in ten-year bands (baseline group 50–60 years) and sex are shown in black boxes

679 with 95% confidence intervals. The size of each square is inversely proportional to the variance of

680 the log odds ratio, so larger boxes indicate greater certainty. Clustering by country is included as a

681 random intercept and heterogeneity is depicted by circles showing the median odds ratio. In panel


682 A, the three symptoms are from the list of fever, cough, fatigue, headache, myalgia, sore throat,













683 rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion; in panel B the two

684 symptoms are from the list fever, myalgia, headache, and sore throat. Patients with missing data for


685 cough, fever or shortness of breath are excluded from all four plots.









**A. Fever and cough, or at least 3 symptoms**




**B. Cough or shortness of breath, or at least 2 symptoms**




**C. Cough or fever**




**D. Cough, fever or shortness of breath**




Fever




Cough




Shortness of breath




Fatigue




Confusion




Nausea &amp; vomiting




Diarrhoea




Muscle pains




Chest pain




Headache




Abdominal pain




Sore throat




A. Fever and cough,  
or at least 3 symptoms



B. Cough or shortness of breath,  
or at least 2 symptoms



C. Cough or fever



D. Cough, fever or shortness of breath

